| |
| |
|
| Insider
Information: |
Wiley Matthew T. |
| Relationship: |
CHIEF COMMERCIAL OFFICER |
| City: |
Rehovot |
| State: |
L3 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
112,238 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$32,285 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
112,238 |
|
|
| Total
Value |
$32,285 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Foamix Pharmaceuticals Ltd |
FOMX |
Chief Commercial Officer |
2020-03-09 |
0 |
2018-12-03 |
0 |
Premium* |
|
|
VYNE Therapeutics Inc |
VYNE |
Chief Commercial Officer |
2021-06-30 |
109,246 |
2020-03-09 |
0 |
Premium* |
|
|
Bioxcel Therapeutics Inc |
BTAI |
CHIEF COMMERCIAL OFFICER |
2024-04-04 |
2,992 |
2024-03-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
21 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BTAI |
Bioxcel Therapeutics Inc |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-04-04 |
4 |
AS |
$2.64 |
$2,656 |
D/D |
(1,008) |
2,992 |
0 |
% |
|
| BTAI |
Bioxcel Therapeutics Inc |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2021-06-30 |
4 |
D |
$3.51 |
$18,080 |
D/D |
(5,151) |
109,246 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2021-03-31 |
4 |
D |
$6.84 |
$17,599 |
D/D |
(2,573) |
114,397 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
27,675 |
116,970 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-12-31 |
4 |
D |
$1.58 |
$2,435 |
D/D |
(1,541) |
357,181 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-11-30 |
4 |
A |
$1.45 |
$11,326 |
D/D |
7,838 |
358,722 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-09-30 |
4 |
D |
$1.66 |
$2,558 |
D/D |
(1,541) |
350,884 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-06-30 |
4 |
D |
$1.73 |
$2,666 |
D/D |
(1,541) |
352,425 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
353,967 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-04-06 |
4 |
D |
$1.40 |
$1,271 |
D/D |
(908) |
203,967 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
137,824 |
204,875 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-03-31 |
4 |
D |
$2.68 |
$1,407 |
D/D |
(525) |
67,051 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2020-03-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(114,074) |
0 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
67,576 |
67,576 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2020-03-02 |
4 |
A |
$2.68 |
$5,336 |
D/D |
1,993 |
114,074 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
41,299 |
112,081 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2019-12-31 |
4 |
D |
$3.28 |
$8,200 |
D/D |
(2,500) |
70,782 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2019-11-29 |
4 |
A |
$2.16 |
$21,249 |
D/D |
9,842 |
73,282 |
0 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2019-03-05 |
4 |
B |
$3.76 |
$50,534 |
D/D |
13,440 |
63,440 |
2.74 |
- |
|
| FOMX |
Foamix Pharmaceuticals Lt... |
Chief Commercial Officer |
• – – |
2018-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
0 |
- |
|
21 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
